Amgen Inc. (NASDAQ:AMGN) Stock Holdings Lifted by Retirement Planning Group LLC

Retirement Planning Group LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 304.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,513 shares of the medical research company’s stock after acquiring an additional 2,644 shares during the quarter. Retirement Planning Group LLC’s holdings in Amgen were worth $1,132,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of AMGN. Hershey Financial Advisers LLC acquired a new stake in Amgen during the 2nd quarter worth about $30,000. nVerses Capital LLC acquired a new stake in shares of Amgen during the second quarter valued at approximately $31,000. Bbjs Financial Advisors LLC purchased a new stake in shares of Amgen in the 2nd quarter valued at approximately $33,000. Matrix Trust Co purchased a new stake in shares of Amgen in the third quarter valued at $36,000. Finally, FSA Wealth Management LLC boosted its position in Amgen by 182.0% during the 1st quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock worth $40,000 after acquiring an additional 91 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Up 2.3 %

Shares of Amgen stock opened at $328.35 on Friday. The company’s fifty day moving average price is $326.06 and its two-hundred day moving average price is $310.75. The firm has a market capitalization of $176.14 billion, a PE ratio of 46.91, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The company had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company’s quarterly revenue was up 20.1% on a year-over-year basis. During the same period in the previous year, the company posted $5.00 earnings per share. On average, analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.74%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio is currently 128.57%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on AMGN shares. Barclays increased their target price on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Royal Bank of Canada restated an “outperform” rating and issued a $362.00 price objective on shares of Amgen in a report on Thursday, September 26th. Bank of America raised their target price on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Finally, Robert W. Baird reiterated an “underperform” rating and set a $215.00 price target on shares of Amgen in a research note on Wednesday, September 25th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $326.30.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.